Press Release - Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and VHFC partner, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit.

Read press release.

Doctors Aren't Sure How To Stop Africa's Deadliest Ebola Outbreak - VHFC researchers report on the devastation in West Africa

In an interview on National Public Radio, Drs. Robert Garry (Tulane University) and Thomas Geisbert (University of Texas Medical Branch) discuss the devastation caused by the raging Ebola outbreak in West Africa, and the challenges health workers are facing.

Growing Ebola Outbreak Threatens to Overwhelm Volunteers - Dr. Robert Garry discusses the situation in Sierra Leone

In a recent article by, Dr. Robert Garry discusses the growing threat of Ebola in Sierra Leone. Dr. Garry, a researcher from Tulane University, has worked on building research capacity on viral hemorrhagic fevers in Sierra Leone for a decade.

Press Release - VHFC responds to confirmed outbreak of Ebola in Sierra Leone

May 27, 2014 - The Viral Hemorrhagic Fever Consortium (VHFC) is very concerned about the recent deaths from Ebola Virus Disease in Koindu, Kailahun District bordering the current Ebola epicenter of Gueckedou, Guinea. Seven samples from that area have since been confirmed to be positive for Zaire ebolavirus at the Lassa Laboratory at Kenema Government Hospital (KGH).

Publication - Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism

VHFC researchers at Tulane University have published findings in the Journal of Virology on an antiviral peptide with potential implications for Lassa fever (LF) treatment. Unlike ribavirin, the only drug currently used to treat LF, the peptide is not acutely toxic, and its activity is highly specific against arenaviruses.

Publication - Lassa Fever in Post-Conflict Sierra Leone

VHFC researchers publish promising results from a five-year Lassa Fever trial conducted in post-conflict Sierra Leone. The trial demonstrated the ability of a rapid diagnostic test, developed by Corgenix Medical and other members of the Consortium, to quickly detect Lassa virus.

Press Release - VHFC responds to ongoing Ebola outbreak

KENEMA, Sierra Leone – March 27, 2014 – A Viral Hemorrhagic Fever Consortium (VHFC) team is assembling in Sierra Leone to respond to the ongoing Ebola outbreak in neighboring Guinea. The Ministry of Health in Guinea has most recently reported a total of 103 suspected cases and 66 deaths mostly in the areas of southeastern Guinea.

Press Release - Corgenix expands Lassa virus rapid test research to Ebola test development

An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.

Publication - Researchers at the Scripps Research Institute make major advances in the fight against Ebola virus

Professor Erica Ollmann Saphire's group at the Scripps Research Institute in La Jolla California has published ground-breaking research into the mechanisms behind how the Ebola virus replicates and spreads.

Corgenix Gains CE Mark for ReLASV® Antigen Rapid Test for Diagnosis of Lassa Fever

VHFC partner, Corgenix Medical Corporation, has developed the first commercialized diagnostic test that enables rapid diagnosis of Lassa viral hemorrhagic fever.

"This 15-minute test has the potential to completely change stye way Lassa fever is detected and treated," said Douglas Simpson, Corgenix President.

Syndicate content
PSD to Drupal theme